TICKERNOMICS Sign up
Last Update: 2024-12-27 15:29:37
Addex Therapeutics Ltd. ( ADXN ) https://www.addextherapeutics.com
7.81USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
Switzerland
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
ADXN
32.82%
SPY
32.66%
-93.93%
ADXN
SPY
108.59%
ADXN
0.00%
SPY
302.52%
ADXN
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1.19
-2.17
0.02
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
0.20
1.89
0.11
-0.76
0.00
0.76
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-1155.71
100.00
-556.42
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
1050.39
-84.83
0.00
Other Earnings and Cash Flow Stats:
Addex Therapeutics Ltd. ( ADXN ) Net Income TTM ($MM) is 5.97
Addex Therapeutics Ltd. ( ADXN ) Operating Income TTM ($MM) is -5.49
Addex Therapeutics Ltd. ( ADXN ) Owners' Earnings Annual ($MM) is -3.68
Addex Therapeutics Ltd. ( ADXN ) Current Price to Owners' Earnings ratio is -156.44
Addex Therapeutics Ltd. ( ADXN ) EBITDA TTM ($MM) is -5.14
Addex Therapeutics Ltd. ( ADXN ) EBITDA Margin is -556.42%
Capital Allocation:
Addex Therapeutics Ltd. ( ADXN ) has paid 0.00 dividends per share and bought back 95.086186 million shares in the past 12 months
Addex Therapeutics Ltd. ( ADXN ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Addex Therapeutics Ltd. ( ADXN ) Interest-bearing Debt ($MM) as of last quarter is 0
Addex Therapeutics Ltd. ( ADXN ) Annual Working Capital Investments ($MM) are -1
Addex Therapeutics Ltd. ( ADXN ) Book Value ($MM) as of last quarter is 11
Addex Therapeutics Ltd. ( ADXN ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Addex Therapeutics Ltd. ( ADXN ) has 3 million in cash on hand as of last quarter
Addex Therapeutics Ltd. ( ADXN ) has 0 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Addex Therapeutics Ltd. ( ADXN ) has 0 common shares outstanding as of last quarter
Addex Therapeutics Ltd. ( ADXN ) has 0 million USD of preferred stock value
Academic Scores:
Addex Therapeutics Ltd. ( ADXN ) Altman Z-Score is -40.38 as of last quarter
Addex Therapeutics Ltd. ( ADXN ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
Addex Therapeutics Ltd. ( ADXN ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of Addex Therapeutics Ltd. ( ADXN ) for the amount of $ on
0.00% of Addex Therapeutics Ltd. ( ADXN ) is held by insiders, and 0.17% is held by institutions
Addex Therapeutics Ltd. ( ADXN ) went public on 2020-01-29
Other Addex Therapeutics Ltd. ( ADXN ) financial metrics:
FCF:-6.75
Unlevered Free Cash Flow:-11.26
EPS:-40.69
Operating Margin:-1155.71
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-55.32
Beta:0.00
Buffet's Owners Earnings:-3.68
Price to Owner's Earnings:-156.44
About Addex Therapeutics Ltd. ( ADXN ) :
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.